NASDAQ$ORIC
ORIC Pharmaceuticals Inc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
ORIC Pharmaceuticals reported financial results and operational updates for Q4 2023.
ORIC Pharmaceuticals reported a net loss of $28.33 million for the fourth quarter of 2023. The company's cash, cash equivalents, and investments totaled $235.0 million as of December 31, 2023, which is expected to fund the operating plan into late 2026.
- Presented initial Phase 1b data from three clinical programs, supporting potential best-in-class profiles for ORIC-944 and ORIC-114.
- Expect to initiate a combination study of ORIC-944 with AR inhibitor(s) in metastatic prostate cancer in the first half of 2024.
- Expect to initiate multiple dose expansion cohorts for ORIC-114 in patients with mutated NSCLC in the first half of 2024.
- Strengthened cash position with $210 million from two private placement financings.
Headline financials
Revenue & EPS history
ORIC Pharmaceuticals · Revenue · Quarterly
$1.54M
Forward guidance
ORIC Pharmaceuticals plans to advance two programs towards the initiation of registrational studies in the second half of 2025.
Tailwinds
- Initiate combination study of ORIC-944 with AR inhibitor(s) in metastatic prostate cancer expected in first half of 2024.
- Provide a program update for ORIC-944 in mid-2024.
- Initiate multiple dose expansion cohorts for ORIC-114 in patients with mutated NSCLC expected in first half of 2024.
- Report updated Phase 1b data for ORIC-114 in the first half of 2025.
- Complete dose escalation for the Phase 1b trial of ORIC-533 in the first quarter of 2024.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2023
+1.2%
Avg return
Earnings day
+1.1%
Avg return
5 days after
+8.0%
Avg return
30 days after
57%
13 / 23 earnings
Positive
+14.7%
Q2 2023
Best reaction
-29.8%
Q4 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +14.7% | +14.9% | +5.7% | |
| Q3 2025 | +0.3% | -5.8% | -23.1% | |
| Q2 2025 | -1.0% | -7.9% | +8.9% | |
| Q1 2025 | +8.7% | +25.8% | +98.9% | |
| Q4 2024 | +0.8% | +2.1% | -43.5% | |
| Q3 2024 | -0.3% | -17.5% | -18.2% | |
| Q1 2024 | -1.0% | -7.4% | -5.6% | |
| Q4 2023 | -4.5% | +0.7% | -33.3% | |
| Q3 2023 | -3.2% | -11.9% | +26.4% | |
| Q2 2023 | +14.7% | +13.8% | +17.3% | |
| Q1 2023 | -0.4% | +0.1% | +11.4% | |
| Q4 2022 | +5.3% | +14.8% | +39.5% | |
| Q3 2022 | +2.8% | +17.9% | +35.4% | |
| Q2 2022 | +3.2% | -2.1% | -26.4% | |
| Q1 2022 | -3.4% | -4.4% | +52.0% | |
| Q4 2021 | -29.8% | -33.0% | -42.6% | |
| Q3 2021 | +7.1% | +8.4% | -7.1% | |
| Q2 2021 | +9.4% | +13.6% | +45.2% | |
| Q1 2021 | +2.1% | +6.1% | -17.0% | |
| Q4 2020 | -6.2% | -7.6% | -10.2% | |
| Q3 2020 | +3.8% | +4.4% | +55.6% | |
| Q2 2020 | +12.5% | +12.4% | +7.8% | |
| Q1 2020 | -8.7% | -11.3% | +7.3% | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro